2026-04-17T02:03:46Zhttps://recercat.cat/oai/requestoai:recercat.cat:11351/127352025-05-03T03:20:39Zcom_2072_378070com_2072_378040col_2072_378092
RECERCAT
author
Müller, Volkmar
author
de Azambuja, Evandro
author
Gempt, Jens
author
Bachelot, Thomas
author
Curigliano, Giuseppe
author
Furtner, Julia
author
Saura Manich, Cristina
2025-05-03T03:20:39Z
2025-05-03T03:20:39Z
2025-03-10T13:07:17Z2025-03-10T13:07:17Z20242025-01
http://hdl.handle.net/11351/12735
Brain metastasis; Breast cancer; PreventionMetástasis cerebral; Cáncer de mama; PrevenciónMetàstasi cerebral; Càncer de mama; PrevencióBackground
Patients with HER2-positive breast cancer have a significant risk of developing brain metastases (BrM), which have detrimental effects on survival outcomes and quality of life. Although there are several systemic treatment options available that may delay the appearance of BrM and secondary progression of previously treated BrM, there are still substantial unmet needs for this patient population and primary prevention remains elusive.
Methods
A group of experts created consensus statements, through a modified Delphi process, to bridge the gap between current unmet needs, available evidence, and international guidelines.
Results
The steering committee reviewed all relevant literature and formed research questions to be answered by the subsequent consensus statements. In total, 61 contributors provided feedback on the consensus statements, with 34 statements reaching agreement out of the 55 statements that were voted on altogether. Statements with consensus aimed to define BrM primary and secondary prevention, screening procedures, assessment of symptoms, treatment efficacy, and preventing the occurrence and progression of BrM, while acknowledging the possibilities and limitations in daily clinical practice. Some statements did not reach agreement for a variety of reasons, mostly due to lack of evidence.
Conclusions
The consensus statements outlined in this publication provide a point of reference for daily clinical practice and can act as recommendations for clinical trial procedures and future guidelines.This work was funded by Seagen who had a role in organising the consensus meetings and outputs; however, they did not take part in the literature grading, consensus surveys or interpretation of results.
Attribution 4.0 International http://creativecommons.org/licenses/by/4.0/ info:eu-repo/semantics/openAccess
Decisió de grup
Mama - Càncer
Cervell - Càncer - Prevenció
Metàstasi
DISEASES::Neoplasms::Neoplasms by Site::Nervous System Neoplasms::Central Nervous System Neoplasms::Brain Neoplasms
Other subheadings::Other subheadings::Other subheadings::/prevention & control
DISEASES::Neoplasms::Neoplasms by Site::Breast Neoplasms
PSYCHIATRY AND PSYCHOLOGY::Behavior and Behavior Mechanisms::Psychology, Social::Group Processes::Consensus
DISEASES::Neoplasms::Neoplastic Processes::Neoplasm Metastasis
ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias del sistema nervioso::neoplasias del sistema nervioso central::neoplasias cerebrales
Otros calificadores::Otros calificadores::Otros calificadores::/prevención & control
ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias de la mama
PSIQUIATRÍA Y PSICOLOGÍA::conducta y mecanismos de la conducta::psicología social::procesos de grupo::consenso
ENFERMEDADES::neoplasias::procesos neoplásicos::metástasis neoplásica
Expert consensus on the prevention of brain metastases in patients with HER2-positive breast cancer
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion